Klaus Seppi

List of Publications by Year
in descending order

289	23,326	8755 75	9861 141
papers	citations	h-index	g-index

298	298	298	19369
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Parkinson disease. Nature Reviews Disease Primers, 2017, 3, 17013.	30.5	3,048
2	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
3	The Movement Disorder Society Evidenceâ€Based Medicine Review Update: Treatments for the nonâ€motor symptoms of Parkinson's disease. Movement Disorders, 2011, 26, S42-80.	3.9	863
4	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. American Journal of Human Genetics, 2011, 89, 168-175.	6.2	757
5	Update on treatments for nonmotor symptoms of Parkinson's diseaseâ€”an evidenceâ€based medicine review. Movement Disorders, 2019, 34, 180-198.	3.9	619
6	International Parkinson and movement disorder society evidenceâ€based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2018, 33, 1248-1266.	3.9	601
7	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Movement Disorders, 2004, 19, 1391-1402.	3.9	481
8	The Movement Disorder Society Evidenceâ€Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2011, 26, S2-41.	3.9	479
9	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	10.2	426
10	The <scp>O</scp>nset of <scp>N</scp>onmotor <scp>S</scp>ymptoms in <scp>P</scp>arkinson's disease (<scp>T</scp>he <scp>ONSET PD</scp><scp>S</scp>tudy). Movement Disorders, 2015, 30, 229-237.	3.9	402
11	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurology, The, 2010, 9, 1070-1077.	10.2	349
12	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	3.7	330
13	Seminar on choreas. Lancet Neurology, The, 2006, 5, 589-602.	10.2	282
14	Prevalence of movement disorders in men and women aged 50â€“89 years (Bruneck Study cohort): a population-based study. Lancet Neurology, The, 2005, 4, 815-820.	10.2	271
15	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
16	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	3.9	222
17	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	3.9	215
18	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	3.9	205

#	Article	IF	Citations
19	White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusionâ€tensor imaging and voxelâ€based morphometry study. Annals of Neurology, 2011, 69, 400-407.	5.3	203
20	The Concept of Prodromal Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2015, 5, 681-697.	2.8	195
21	Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Annals of Neurology, 2005, 58, 630-634.	5.3	193
22	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Movement Disorders, 2014, 29, 857-867.	3.9	193
23	Magnetic resonance imaging for the diagnosis of Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 915-964.	2.8	178
24	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2018, 33, 1601-1608.	3.9	171
25	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology, 2015, 84, 654-658.	1.1	164
26	Minocycline 1â€year therapy in multipleâ€systemâ€atrophy: Effect on clinical symptoms and [¹¹C] (R)â€PK11195 PET (MEMSAâ€trial). Movement Disorders, 2010, 25, 97-107.	3.9	163
27	Grading of neuropathology in multiple system atrophy: Proposal for a novel scale. Movement Disorders, 2005, 20, S29-S36.	3.9	161
28	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Annals of Neurology, 2017, 82, 419-428.	5.3	161
29	Longâ€term antidyskinetic efficacy of amantadine in Parkinson's disease. Movement Disorders, 2010, 25, 1357-1363.	3.9	159
30	Voxelâ€based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Movement Disorders, 2003, 18, 1132-1138.	3.9	153
31	Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60â€“97 Years: A Population-Based Study. PLoS ONE, 2013, 8, e69627.	2.5	151
32	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. NeuroImage, 2004, 21, 1443-1451.	4.2	149
33	Soluble Receptor Activator of Nuclear Factor-ÎºB Ligand and Risk for Cardiovascular Disease. Circulation, 2007, 116, 385-391.	1.6	148
34	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. Archives of Neurology, 2011, 68, 932.	4.5	146
35	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Movement Disorders, 2009, 24, 949-964.	3.9	145
36	Differentiation of Malignant and Benign Musculoskeletal Tumors: Combined Color and Power Doppler US and Spectral Wave Analysis. Radiology, 2002, 223, 410-416.	7.3	141

#	Article	IF	Citations
37	Metaâ€analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. Movement Disorders, 2017, 32, 619-623.	3.9	129
38	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). Movement Disorders, 2006, 21, 179-186.	3.9	126
39	Neurological outcome and quality of life 3Âmonths after COVIDâ€19: A prospective observational cohort study. European Journal of Neurology, 2021, 28, 3348-3359.	3.3	126
40	Dorsolateral nigral hyperintensity on 3.0T susceptibilityâ€weighted imaging in neurodegenerative Parkinsonism. Movement Disorders, 2015, 30, 1068-1076.	3.9	125
41	Voxel based morphometry reveals specific gray matter changes in primary dystonia. Movement Disorders, 2007, 22, 1538-1542.	3.9	121
42	Enteric nervous system Î±-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology, 2015, 85, 1761-1768.	1.1	121
43	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain, 2006, 129, 538-542.	7.6	120
44	Significance of MRI in Diagnosis and Differential Diagnosis of Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2010, 7, 300-318.	1.4	116
45	Voxel-wise analysis of [123I]Î²-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain, 2005, 128, 1605-1612.	7.6	115
46	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	3.9	114
47	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Movement Disorders, 2013, 28, 216-219.	3.9	112
48	Restless legs syndrome in Parkinson's disease. Movement Disorders, 2009, 24, 2076-2080.	3.9	111
49	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. Parkinsonism and Related Disorders, 2017, 40, 1-10.	2.2	110
50	Progression of brain atrophy in multiple system atrophy. Journal of Neurology, 2007, 254, 191-196.	3.6	108
51	Mortality in Parkinson's disease: A 20â€year followâ€up study. Movement Disorders, 2009, 24, 819-825.	3.9	108
52	Healthâ€related quality of life in multiple system atrophy. Movement Disorders, 2006, 21, 809-815.	3.9	102
53	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. NeuroImage, 2006, 31, 240-245.	4.2	98
54	International Guidelines for the Treatment of Huntington's Disease. Frontiers in Neurology, 2019, 10, 710.	2.4	98

#	Article	IF	Citations
55	Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet Journal of Rare Diseases, 2014, 9, 161.	2.7	96
56	Left hemispheric predominance of nigrostriatal dysfunction in Parkinsonâ€™s disease. Brain, 2012, 135, 3348-3354.	7.6	95
57	Mortality in Parkinson's disease: A 38â€year followâ€up study. Movement Disorders, 2015, 30, 266-269.	3.9	95
58	An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Current Opinion in Neurology, 2005, 18, 370-375.	3.6	92
59	Diffusion weighted imaging best discriminates PD from MSAâ€P: A comparison with tilt table testing and heart MIBG scintigraphy. Movement Disorders, 2007, 22, 1771-1776.	3.9	92
60	The role of highâ€field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Movement Disorders, 2017, 32, 510-525.	3.9	92
61	Apomorphine for Parkinsonâ€™s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs, 2019, 33, 905-918.	5.9	92
62	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain, 2021, 144, 1118-1126.	7.6	92
63	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Movement Disorders, 2009, 24, 1906-1909.	3.9	91
64	Brain Magnetic Resonance Imaging Techniques in the Diagnosis of Parkinsonian Syndromes. Neuroimaging Clinics of North America, 2010, 20, 29-55.	1.0	91
65	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 145-152.	10.2	90
66	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibilityâ€weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Annals of Neurology, 2016, 79, 1026-1030.	5.3	90
67	Polycystic ovaries, obesity and insulin resistance in women with epilepsy. Journal of Neurology, 2002, 249, 835-841.	3.6	89
68	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology, 2016, 86, 1242-1249.	1.1	89
69	Comparison of diffusionâ€weighted imaging and [¹²³I]IBZMâ€SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Movement Disorders, 2004, 19, 1438-1445.	3.9	86
70	Probable RBD and association with neurodegenerative disease markers: A populationâ€based study. Movement Disorders, 2015, 30, 1417-1421.	3.9	86
71	Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. Sleep Medicine, 2015, 16, 186-189.	1.6	86
72	Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Movement Disorders, 2006, 21, 1109-1113.	3.9	82

#	Article	IF	Citations
73	Video-EEG monitoring: Safety and adverse events in 507 consecutive patients. Epilepsia, 2011, 52, 443-452.	5.1	82
74	Causeâ€specific mortality among patients with epilepsy: Results from a 30â€year cohort study. Epilepsia, 2013, 54, 495-501.	5.1	82
75	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	10.2	82
76	Genome-wide association study in essential tremor identifies three new loci. Brain, 2016, 139, 3163-3169.	7.6	78
77	Which dyskinesia scale best detects treatment response?. Movement Disorders, 2013, 28, 341-346.	3.9	76
78	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrainâ€toâ€pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Movement Disorders, 2010, 25, 2444-2449.	3.9	74
79	Fiveâ€year followâ€up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Movement Disorders, 2014, 29, 1774-1780.	3.9	74
80	Characterizing advanced Parkinsonâ€™s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology, 2019, 19, 50.	1.8	74
81	Multiple system atrophy. International Review of Neurobiology, 2019, 149, 137-192.	2.0	74
82	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. The Lancet Digital Health, 2019, 1, e222-e231.	12.3	73
83	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
84	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. Annals of Neurology, 2021, 90, 62-75.	5.3	73
85	Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia. Neurodegenerative Diseases, 2007, 4, 428-430.	1.4	72
86	Riluzole in Huntington's disease (HD): an open label study with one year follow up. Journal of Neurology, 2001, 248, 866-869.	3.6	71
87	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. Movement Disorders, 2016, 31, 1405-1408.	3.9	71
88	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. Movement Disorders, 2003, 18, 319-323.	3.9	70
89	Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxelâ€based morphometry study. Movement Disorders, 2006, 21, 159-165.	3.9	67
90	Differences in <scp>MDS</scp>â€<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice, 2017, 4, 536-544.	1.5	65

#	Article	IF	Citations
91	The reorganization of functional architecture in the early-stages of Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 61-68.	2.2	64
92	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinsonâ€™s Disease: A Cross-Sectional Study. Gerontology, 2019, 65, 216-228.	2.8	63
93	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. Movement Disorders, 2006, 21, 847-852.	3.9	62
94	Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. European Heart Journal, 2005, 26, 279-287.	2.2	60
95	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. Movement Disorders, 2017, 32, 1457-1464.	3.9	60
96	Topography of Dopamine Transporter Availability in Progressive Supranuclear Palsy. Archives of Neurology, 2006, 63, 1154.	4.5	59
97	Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study. Journal of Neurology, 2015, 262, 126-133.	3.6	59
98	Neurological outcomes 1Âyear after COVIDâ€19 diagnosis: A prospective longitudinal cohort study. European Journal of Neurology, 2022, 29, 1685-1696.	3.3	57
99	Progression of parkinsonism in multiple system atrophy. Journal of Neurology, 2005, 252, 91-96.	3.6	55
100	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. Movement Disorders, 2016, 31, 1408-1413.	3.9	55
101	Nonâ€Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Annals of Neurology, 2020, 88, 712-722.	5.3	55
102	Social and clinical determinants of quality of life in Parkinsonâ€™s disease in Austria: a cohort study. Journal of Neurology, 2010, 257, 638-645.	3.6	53
103	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A populationâ€based 10â€year study. Movement Disorders, 2018, 33, 405-413.	3.9	53
104	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinsonâ€™s disease. Brain, 2013, 136, 3028-3037.	7.6	52
105	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Movement Disorders, 2015, 30, 1885-1892.	3.9	52
106	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. Movement Disorders, 2009, 24, S711-20.	3.9	49
107	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism and Related Disorders, 2018, 54, 90-94.	2.2	49
108	European Academy of Neurology/Movement Disorder Societyâ€European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. Movement Disorders, 2022, 37, 1360-1374.	3.9	49

#	Article	IF	Citations
109	Freezing of gait in postmortemâ€confirmed atypical parkinsonism. Movement Disorders, 2002, 17, 1041-1045.	3.9	46
110	White and Gray Matter Abnormalities in Narcolepsy with Cataplexy. Sleep, 2012, 35, 345-351.	1.1	46
111	Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. Journal of the Neurological Sciences, 2013, 332, 21-29.	0.6	46
112	Brain structural profile of multiple system atrophy patients with cognitive impairment. Journal of Neural Transmission, 2017, 124, 293-302.	2.8	46
113	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism and Related Disorders, 2018, 52, 83-89.	2.2	46
114	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Movement Disorders, 2010, 25, 1464-1469.	3.9	45
115	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism and Related Disorders, 2018, 46, 47-55.	2.2	45
116	Seeing ophthalmologic problems in Parkinson disease. Neurology, 2020, 94, e1539-e1547.	1.1	45
117	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0189897.	2.5	44
118	Sensorâ€based gait analysis in atypical parkinsonian disorders. Brain and Behavior, 2018, 8, e00977.	2.2	43
119	Diffusion-weighted imaging in Huntington's disease. Movement Disorders, 2006, 21, 1043-1047.	3.9	41
120	Mortality in Parkinson's disease, a 20â€year followâ€up study. Movement Disorders, 2010, 25, 661-662.	3.9	41
121	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. NeuroReport, 2004, 15, 1711-1714.	1.2	40
122	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]Î²-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1012-1020.	6.4	40
123	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. Neuroscience Letters, 2015, 602, 145-149.	2.1	40
124	Genetic analysis of candidate genes modifying the age-at-onset in Huntingtonâ€™s disease. Human Genetics, 2006, 120, 285-292.	3.8	39
125	An open trial of levetiracetam for segmental and generalized dystonia. Movement Disorders, 2007, 22, 1649-1651.	3.9	38
126	Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. Journal of Magnetic Resonance Imaging, 2007, 25, 564-569.	3.4	38

#	Article	IF	Citations
127	Risk factors and prodromal markers and the development of Parkinsonâ€™s disease. Journal of Neurology, 2014, 261, 180-187.	3.6	38
128	Augmentation and impulsive behaviors in restless legs syndrome. Neurology, 2016, 87, 36-40.	1.1	38
129	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. Movement Disorders, 2020, 35, 976-983.	3.9	38
130	Abnormalities of dopaminergic neurotransmission in SCA2: A combined ¹²³Iâ€²CIT and ¹²³Iâ€IBZM SPECT study. Movement Disorders, 2004, 19, 1320-1325.	3.9	37
131	Computerized Tremor Analysis of Valproate-induced Tremor: A Comparative Study of Controlled-release versus Conventional Valproate. Epilepsia, 2005, 46, 320-323.	5.1	37
132	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. Movement Disorders, 2019, 34, 1041-1048.	3.9	36
133	Towards translational therapies for multiple system atrophy. Progress in Neurobiology, 2014, 118, 19-35.	5.7	35
134	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 156-160.	1.5	35
135	Cerebrospinal fluid hypocretinâ€1 levels in multiple system atrophy. Movement Disorders, 2007, 22, 1822-1824.	3.9	34
136	Cannabinoids for Treatment of Dystonia in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2018, 7, 167-173.	1.9	33
137	Parkinson's disease and arithmetics: The role of executive functions. Journal of the Neurological Sciences, 2006, 248, 124-130.	0.6	32
138	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. Movement Disorders, 2012, 27, 1182-1185.	3.9	32
139	Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI. Neurology, 2014, 82, 1752-1752.	1.1	32
140	Nonmotor <scp>S</scp>ymptoms in <scp>S</scp>ubjects <scp>W</scp>ithout <scp>E</scp>vidence of <scp>D</scp>opaminergic <scp>D</scp>eficits. Movement Disorders, 2015, 30, 976-981.	3.9	32
141	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
142	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
143	Cognition in multiple system atrophy: a singleâ€center cohort study. Annals of Clinical and Translational Neurology, 2020, 7, 219-228.	3.7	31
144	Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. NeuroImage, 2003, 20, 1253-1263.	4.2	30

#	Article	IF	Citations
145	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	2.4	30
146	Gait and postural disorders in parkinsonism: a clinical approach. Journal of Neurology, 2020, 267, 3169-3176.	3.6	30
147	Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. Clinical Neurophysiology, 2003, 114, 541-547.	1.5	29
148	Deep brain stimulation in Huntington's disease: A 4â€yearâ€up case report. Movement Disorders, 2012, 27, 806-807.	3.9	29
149	Riluzole therapy in cervical dystonia. Movement Disorders, 2002, 17, 198-200.	3.9	28
150	Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study. Neurodegenerative Diseases, 2013, 12, 212-218.	1.4	28
151	Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. Movement Disorders, 2006, 21, 1281-1283.	3.9	27
152	A novel computer-assisted image analysis of [123I]Î²-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 702-710.	6.4	27
153	Predictors for mild parkinsonian signs: A prospective population-based study. Parkinsonism and Related Disorders, 2015, 21, 321-324.	2.2	27
154	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 49, 81-87.	2.2	27
155	Structural Imaging in Atypical Parkinsonism. International Review of Neurobiology, 2018, 142, 67-148.	2.0	27
156	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. Annals of Neurology, 2020, 88, 643-645.	5.3	27
157	MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. Parkinsonism and Related Disorders, 2007, 13, S400-S405.	2.2	26
158	The influence of deep brain stimulation on pain perception in Parkinson's disease. Movement Disorders, 2011, 26, 1367-1368.	3.9	26
159	Neuroimaging: Current role in detecting preâ€motor Parkinson's disease. Movement Disorders, 2012, 27, 634-643.	3.9	26
160	Auditory startle response in cervical dystonia. Movement Disorders, 2003, 18, 1522-1526.	3.9	25
161	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology, 2020, 95, e2854-e2865.	1.1	25
162	New hopes for disease modification in Parkinson's Disease. Neuropharmacology, 2020, 171, 108085.	4.1	25

#	Article	IF	Citations
163	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.1	23
164	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. Parkinsonism and Related Disorders, 2019, 67, 60-65.	2.2	23
165	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. Parkinsonism and Related Disorders, 2020, 70, 51-54.	2.2	23
166	Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder. Neurology, 2020, 94, e1605-e1613.	1.1	23
167	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Science, 2012, 10, 71.	1.7	22
168	Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. Cerebellum, 2012, 11, 223-226.	2.5	22
169	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. Movement Disorders, 2021, 36, 681-689.	3.9	22
170	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Clinical Autonomic Research, 2021, 31, 157-164.	2.5	22
171	European Academy of Neurology/Movement Disorder Society â€•European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. European Journal of Neurology, 2022, 29, 2580-2595.	3.3	22
172	Early distinction of Parkinsonâ€variant multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 440-441.	3.9	21
173	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. Movement Disorders Clinical Practice, 2022, 9, 6-19.	1.5	21
174	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. Translational Neurodegeneration, 2022, 11, 11.	8.0	21
175	Consistency of â€œProbable <scp>RBD</scp>â€•Diagnosis with the <scp>RBD</scp> Screening Questionnaire: A Followâ€up Study. Movement Disorders Clinical Practice, 2017, 4, 403-405.	1.5	20
176	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): Placebo-controlled, polysomnographic case report. Movement Disorders, 2001, 16, 1177-1179.	3.9	19
177	Urinary retention discriminates multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 1926-1928.	3.9	19
178	An <scp>MDS</scp> Evidenceâ€Based Review on Treatments for Huntington's Disease. Movement Disorders, 2022, 37, 25-35.	3.9	19
179	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. Movement Disorders, 2012, 27, 1683-1685.	3.9	18
180	Multiple system atrophy as emerging template for accelerated drug discovery in Î±-synucleinopathies. Parkinsonism and Related Disorders, 2014, 20, 793-799.	2.2	18

#	Article	IF	Citations
181	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. Parkinsonism and Related Disorders, 2017, 38, 102-103.	2.2	18
182	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. Journal of Neural Transmission, 2017, 124, 1029-1036.	2.8	18
183	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism and Related Disorders, 2020, 77, 57-63.	2.2	18
184	Factors associated with impaired quality of life three months after being diagnosed with COVID-19. Quality of Life Research, 2022, 31, 1401-1414.	3.1	18
185	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
186	Characterization of gait variability in multiple system atrophy and Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 1770-1779.	3.6	18
187	Drug safety evaluation of rotigotine. Expert Opinion on Drug Safety, 2012, 11, 503-512.	2.4	17
188	Is transcranial sonography useful to distinguish drugâ€induced parkinsonism from Parkinson's disease?. Movement Disorders, 2012, 27, 1194-1196.	3.9	17
189	A follow-up study of substantia nigra echogenicity in healthy adults. Movement Disorders, 2012, 27, 1196-1197.	3.9	17
190	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. Movement Disorders, 2016, 31, 579-583.	3.9	17
191	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
192	Association of Essential Tremor With Novel Risk Loci. JAMA Neurology, 2022, 79, 185.	9.0	17
193	Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsyâ€Parkinsonism</scp> From <scp>Parkinson's Disease</scp>. Movement Disorders, 2022, 37, 1272-1281.	3.9	17
194	Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy). Experimental Neurology, 2000, 164, 166-175.	4.1	16
195	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. Parkinsonism and Related Disorders, 2019, 58, 23-27.	2.2	16
196	Nabilone for non-motor symptoms of Parkinsonâ€™s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). Journal of Neural Transmission, 2019, 126, 1061-1072.	2.8	16
197	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 87-91.	2.2	16
198	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinsonâ€™s disease. Sleep, 2021, 44, .	1.1	16

#	Article	IF	Citations
199	Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathologica, 2003, 106, 188-189.	7.7	15
200	Nonmotor symptoms in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2013, 13, 581-583.	2.8	15
201	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. Journal of Parkinson's Disease, 2019, 9, 681-691.	2.8	15
202	Automated Analysis of Diffusionâ€Weighted <scp>Magnetic Resonance Imaging</scp> for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. Movement Disorders, 2021, 36, 241-245.	3.9	15
203	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). PLoS ONE, 2015, 10, e0145493.	2.5	14
204	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Movement Disorders, 2016, 31, 1577-1581.	3.9	14
205	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. PLoS ONE, 2017, 12, e0174793.	2.5	14
206	Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clinical Interventions in Aging, 2012, 7, 83.	2.9	13
207	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13
208	In Vivo Magnetic Resonance Imaging of Embryonic Neural Grafts in a Rat Model of Striatonigral Degeneration (Multiple System Atrophy). NeuroImage, 2000, 12, 209-218.	4.2	12
209	Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntingtonâ€™s disease. International Clinical Psychopharmacology, 2013, 28, 1.	1.7	12
210	Towards seeing the visual impairments in Parkinsonâ€™s disease: protocol for a multicentre observational, cross-sectional study. BMC Neurology, 2019, 19, 141.	1.8	11
211	Has Deep Brain Stimulation Changed the Very Longâ€Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. Movement Disorders Clinical Practice, 2020, 7, 782-787.	1.5	11
212	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal <scp>Populationâ€Based</scp> Cohort. Movement Disorders, 2020, 35, 1658-1662.	3.9	11
213	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. Parkinsonism and Related Disorders, 2020, 72, 65-71.	2.2	11
214	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Populationâ€Based 10â€Year Study. Movement Disorders, 2021, 36, 1464-1466.	3.9	11
215	Undetected ophthalmological disorders in Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 3821-3832.	3.6	11
216	Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. Movement Disorders, 2007, 22, 174-178.	3.9	10

#	Article	IF	Citations
217	Reflection impulsivity perceptual decisionâ€making in patients with restless legs syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 315-322.	3.7	10
218	Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging. Human Brain Mapping, 2021, 42, 4809-4822.	3.6	10
219	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. Journal of Parkinson's Disease, 2022, 12, 1369-1387.	2.8	10
220	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Postâ€hoc Analysis of <scp>NMSâ€Nab</scp> Study. Movement Disorders Clinical Practice, 2022, 9, 751-758.	1.5	10
221	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. Movement Disorders, 2016, 31, 235-240.	3.9	9
222	Time will tell: Decision making in premanifest and manifest Huntingtonâ€™s disease. Brain and Behavior, 2020, 10, e01843.	2.2	9
223	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. Movement Disorders, 2016, 31, 1925-1927.	3.9	8
224	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. Annals of Clinical and Translational Neurology, 2020, 7, 1620-1627.	3.7	8
225	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. Parkinsonism and Related Disorders, 2021, 85, 30-36.	2.2	8
226	Sensitivity to Change and Patientâ€Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Dataâ€Driven Analysis. Movement Disorders, 2022, 37, 1425-1431.	3.9	8
227	Neuropathologic Changes in Parkinson Disease With Late Onset of Dementia. Archives of Neurology, 2003, 60, 452.	4.5	7
228	Plasma fasting cholesterol profiles and age at onset in <scp>P</scp>arkinson's disease. Movement Disorders, 2015, 30, 1974-1975.	3.9	7
229	Motoric cognitive risk syndrome: Multicenter incidence study. Neurology, 2015, 85, 388-389.	1.1	7
230	A Standardized <scp>MR</scp> Imaging Protocol for Parkinsonism. Movement Disorders, 2020, 35, 1745-1750.	3.9	7
231	Laboratoryâ€Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <scp>MoDiMSA Study Group</scp>. Movement Disorders Clinical Practice, 2021, 8, 322-340.	1.5	7
232	Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis. Journal of Neural Transmission, 2021, 128, 1497-1505.	2.8	7
233	Cardiac sympathetic innervation in Parkinsonâ€™s disease versus multiple system atrophy. Clinical Autonomic Research, 2022, 32, 103-114.	2.5	7
234	Differentiating Parkinsonâ€™s Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1115-1123.	2.8	7

#	Article	IF	Citations
235	Symptomatic Care in Multiple System Atrophy: State of the Art. Cerebellum, 2023, 22, 433-446.	2.5	7
236	Disease Progression in Multiple System Atrophyâ€"Novel Modeling Framework and Predictive Factors. Movement Disorders, 2022, 37, 1719-1727.	3.9	7
237	Dementia with Lewy bodies and Parkinson disease with dementia: Can MRI make the difference?. Neurology, 2007, 69, 717-718.	1.1	6
238	Pramipexole extended release in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2011, 11, 1229-1234.	2.8	6
239	Axial myopathy in parkinsonism. Movement Disorders, 2011, 26, 1569-1571.	3.9	6
240	Effects of self-administered cannabidiol in a patient with multiple system atrophy. Clinical Autonomic Research, 2020, 30, 355-356.	2.5	6
241	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. Movement Disorders Clinical Practice, 2021, 8, 1052-1060.	1.5	6
242	Synonymous mutation in adenosine triphosphatase copperâ€transporting beta causes enhanced exon skipping in Wilson disease. Hepatology Communications, 2022, 6, 1611-1619.	4.3	6
243	Overstimulation of the Î±1B-adrenergic receptor causes a â€œseizure plusâ€•syndrome. Nature Medicine, 2001, 7, 132-132.	30.7	5
244	Substantia nigra hypoechogenicity in Friedreich ataxia. Movement Disorders, 2012, 27, 332-333.	3.9	5
245	Relevance of EARLYSTIM in a tertiary movement disorders center. Movement Disorders, 2014, 29, 1220-1221.	3.9	5
246	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
247	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. Neurology, 2018, 90, 940-940.	1.1	5
248	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. European Radiology, 2020, 30, 2802-2808.	4.5	5
249	The Parkinson disease connectome â€" insights from new imaging studies. Nature Reviews Neurology, 2021, 17, 527-528.	10.1	5
250	Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. Parkinsonism and Related Disorders, 2022, 101, 43-48.	2.2	5
251	Very lateâ€onset pure autonomic failure. Movement Disorders, 2017, 32, 1106-1108.	3.9	4
252	Insulin signalling: new target for Parkinson's treatments?. Lancet, The, 2017, 390, 1628-1630.	13.7	4

#	Article	IF	Citations
253	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. Movement Disorders Clinical Practice, 2017, 4, 389-396.	1.5	4
254	Shaker-related voltage-gated potassium channels Kv1 in human hippocampus. Brain Structure and Function, 2018, 223, 2663-2671.	2.3	4
255	The Frontal Assessment Battery in RLS patients with and without augmentation. Sleep Medicine, 2020, 75, 456-458.	1.6	4
256	Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders. Brain Sciences, 2021, 11, 383.	2.3	4
257	Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. Parkinsonism and Related Disorders, 2021, 84, 155-163.	2.2	4
258	Eye Tracking in Patients with Parkinsonâ€™s Disease Treated with Nabiloneâ€“Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. Brain Sciences, 2022, 12, 661.	2.3	4
259	Lewy bodies in patients presenting clinically with Alzheimer disease. Journal of Alzheimer's Disease, 2002, 4, 327-328.	2.6	3
260	INTENSIVE CARE MANAGEMENT IN VERY OLD ADULTS: TWO CASES WITH CLOSTRIDIUM TETANI INFECTION. Journal of the American Geriatrics Society, 2011, 59, 552-553.	2.6	3
261	Perimenstrual Fluctuations in Two Siblings With Earlyâ€Onset Parkinson's Disease. Movement Disorders Clinical Practice, 2014, 1, 125-127.	1.5	3
262	Imaging markers of disease progression in multiple system atrophy. Future Neurology, 2019, 14, FNL24.	0.5	3
263	Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report. BMC Neurology, 2020, 20, 89.	1.8	3
264	The footprint of orthostatic hypotension in parkinsonian syndromes. Parkinsonism and Related Disorders, 2020, 77, 107-109.	2.2	3
265	Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study. Gerontology, 2022, 68, 1139-1144.	2.8	3
266	Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the <scp>OBSERVEâ€PD</scp> observational study. Acta Neurologica Scandinavica, 2022, 146, 167-176.	2.1	3
267	Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]Î²-CIT SPECT analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1084-1090.	6.4	2
268	Managing the Non-Motor Symptoms of Parkinson's Disease. , 2008, , 91-120.		2
269	Structural MRI in Idiopathic Parkinson Disease and Parkinsonism. , 2013, , 105-128.		2
270	Letter re: Incident parkinsonism in older adults without Parkinson disease. Neurology, 2017, 88, 919-919.	1.1	2

#	Article	IF	Citations
271	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eyeâ€Tracking Study. Movement Disorders, 2021, 36, 1246-1250.	3.9	2
272	The role of arterial spin labeling, a noninvasive MRI perfusion method, in identifying an abnormal cerebral perfusion pattern in Parkinson's disease. Movement Disorders, 2011, 26, 1197-1197.	3.9	1
273	Invasive Treatment Strategies in a Patient with <scp>PARK</scp> 15â€“Associated Parkinsonism. Movement Disorders Clinical Practice, 2015, 2, 434-435.	1.5	1
274	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. Neurology, 2016, 87, 2603-2603.	1.1	1
275	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. Radiology, 2016, 281, 651-652.	7.3	1
276	Diagnosis of PSP-P: Can a newly developed MRPI make the difference?. Parkinsonism and Related Disorders, 2018, 54, 1-2.	2.2	1
277	Extending the spectrum of non-motor symptoms with olfaction in pre-motor Huntingtonâ€™s disease â€“ a pilot study. Neurodegenerative Diseases, 2020, 20, 207-211.	1.4	1
278	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. Movement Disorders, 2021, 36, 2703-2705.	3.9	1
279	Tit for Tat: Costly Punishment in Manifest Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2021, 21, 74-78.	1.4	1
280	Factors associated with augmentation in patients with restless legs syndrome. European Journal of Neurology, 2022, 29, 1227-1231.	3.3	1
281	Treatment of dementia in Parkinson's disease. The Cochrane Library, 2005, , .	2.8	0
282	Treatment of psychosis in ParkinsonÂ´s disease. The Cochrane Library, 2005, , .	2.8	0
283	Reply: â€œRestless Legs Syndrome and Parkinson's Diseaseâ€• Movement Disorders, 2010, 25, 1314-1315.	3.9	0
284	Multiple System Atrophy. Blue Books of Neurology, 2010, 34, 340-359.	0.1	0
285	Magnetic resonance imaging of multiple system atrophy. , 0, , 167-203.		0
286	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. Movement Disorders, 2016, 31, 1588-1589.	3.9	0
287	Comment: Autologous mesenchymal stem cells. Neurology, 2019, 93, 25-25.	1.1	0
288	Reply to: â€œExperience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsyâ€• Movement Disorders, 2021, 36, 2208-2209.	3.9	0

#	Article	IF	Citations
289	Hospital Admissions of HuntingtonÂ´s Disease patients in a HuntingtonÂ´s Disease centre between 2011 and 2016: a retrospective analysis. Movement Disorders Clinical Practice, 0, , .	1.5	0